Prescribing information

 

       

The ENERZAIR® BREEZHALER® device provides confidence that the full dose has been taken

 
50%

50%

of patients are unable to use their inhaler properly, even with training§4

 

How to use the BREEZHALER® device

Watch the following video to learn how to use the BREEZHALER®.

Unlock the potential of inhaled asthma care with once-daily ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)

 

*Data derived from studies in COPD patients using available treatments for COPD in the BREEZHALER devices.2,3
In a study where 262 healthcare professionals assessed the handling of 3,393 devices used for continuous treatment of COPD in 2,935 patients. Devices assessed were BREEZHALER® (n=876), Diskus® (n=452), Handihaler®  (n=598), Pressurised metered-dose inhaler (pMDI) (n=422), Respimat® (n=625) and Turbuhaler® (n=420).2
Compared to Ellipta® and HandiHaler®.3
§96 pharmacies collected data from 570 adult asthma patients in Australia. Of these, 348 patients were taking preventer/combination medication on a regular basis and were included. All patients who demonstrated incorrect technique at Visit 1 were trained to mastery. Of these, data was available for 238 at follow-up visit.4
ENERZAIR® BREEZHALER® is not licensed for treatment of COPD.

Respimat® is a registered trademark of Boehringer Ingelheim. Ellipta® and Accuhaler® are registered trademarks of GlaxoSmithKline. Turbohaler® is a registered trademark of AstraZeneca.

Indication: ENERZAIR® BREEZHALER® is indicated as a maintenance for treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.1

CI, confidence interval; COPD, chronic obstructive pulmonary disease.

References

  1. ENERZAIR® BREEZHALER® Summary of Product Characteristics
  2. Molimard M et al. Eur Respir J 2017;49:1601794.
  3. Altman P et al. BMC Pulm Med 2018;18:100.
  4. Azzi E et al. NPJ Prim Care Respir Med 2017;27:29.
Rate this content: 
No votes yet
UK | March 2021 | 103405
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]